Alzheimer’s disease (AD) is a devastating illness in elderly individuals, that currently has no known cure. Causal genetic factors only account for 1-2% of AD patients. However, other causal factors are still unknown for a majority of AD patients. Currently, multiple factors are implicated in late-onset AD, including unhealthy diet, physical inactivity, traumatic brain injury, chronic conditions, epigenetic factors, and environmental exposures. Although clinical symptoms of dementia are common to all races and ethnic groups, conditions that lead to dementia are different in terms of lifestyle, genetic profile, and socio-economic conditions. Increasing evidence also suggests that some elderly individuals age without cognitive impairments in their 60–90s as seen in rural West Texas, while some individuals progress with chronic conditions and cognitive impairments into their 60s. To understand these discriminations, we assessed current literature on demographic features of health in rural West Texas. This paper also outlines our initiated clinical study with a purpose of understanding the factors that allow some individuals to live without cognitive impairments at the age of 60–90 years, whereas others develop deficits in cognitive function around or above 60 years. Our ongoing study hopes to determine the factors that delay aging in some individuals by investigating various aspects including genetics, epigenetics, ethnicity, biology, culture, and lifestyle. This will be achieved by gathering information about participants’ ethnographic profiles, cognitive assessments, blood-profiles, brain scans, and blood-based genomic analyses in relation to lifestyle. The outcomes of our study will provide insights into healthy aging in rural West Texas.
Alzheimer’s Disease International (2018) World Alzheimer Report 2018. The state of the art of dementia research: New frontiers. https://www.alzint.org/u/WorldAlzheimerReport2018.pdf, Last updated September 21, 2018, Accessed on December 22, 2021.
2.
KumarS, ReddyPH (2020) The role of synaptic microRNAs in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis1866, 165937.
3.
GowdaP, ReddyPH, KumarS (2022) Deregulated mitochondrial microRNAs in Alzheimer’s disease: Focus on synapse and mitochondria. Ageing Res Rev73, 101529.
4.
McGeerPL, RogersJ, McGeerEG (2016) Inflammation, antiinflammatory agents, and Alzheimer’s disease: The last 22 years. J Alzheimers Dis54, 853–857.
5.
MortonH, KshirsagarS, OrlovE, BunquinLE, SawantN, BolengL, GeorgeM, BasuT, RamasubramanianB, PradeepkiranJA, KumarS, VijayanM, ReddyAP, ReddyPH (2021) Defective mitophagy and synaptic degeneration in Alzheimer’s disease: Focus on aging, mitochondria and Synapse. Free Radic Biol Med172, 652–667.
6.
SwerdlowRH, HuiD, ChaliseP, SharmaP, WangX, AndrewsSJ, PaJ, MahnkenJD, MorrisJ, WilkinsHM, BurnsJM, MichaelisML, MichaelisEK (2020) Exploratory analysis of mtDNA haplogroups in two Alzheimer’s longitudinal cohorts. Alzheimers Dement16, 1164–1172.
7.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
8.
ReddyPH, BealMF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med14, 45–53.
9.
DuH, GuoL, FangF, ChenD, A SosunovA, M McKhannG, YanY, WangC, ZhangH, MolkentinJD, Gunn-MooreFJ, VonsattelJP, ArancioO, ChenJX, YanSD (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med14, 1097–1105.
10.
KametaniF, HasegawaM (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci12, 25.
11.
Sadigh-EteghadS, SabermaroufB, MajdiA, TalebiM, FarhoudiM, MahmoudiJ (2014) Amyloid-beta: A crucial factor in Alzheimer’s disease. Med Princ Pract24, 1–10.
12.
ReddyPH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res1415, 136–148.
13.
AshrafianH, ZadehEH, KhanRH (2021) Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol167, 382–394.
14.
HondiusDC, KoopmansF, LeistnerC, Pita-IllobreD, Peferoen-BaertRM, MarbusF, PaliukhovichI, LiKW, RozemullerAJ, HoozemansJJ, SmitAB (2021) The proteome of granulovacuolar degeneration and neurofibrillary tangles in Alzheimer’s disease. Acta Neuropathol141, 341–358.
ReddyPH (2019) Lifestyle and risk factors of dementia in rural West Texas. J Alzheimers Dis72(s1), S1–S10.
17.
NowrangiMA, RaoV, LyketsosCG (2011) Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am34, 275–294.
18.
MielkeMM, FerrettiMT, IulitaMF, HaydenK, KhachaturianAS (2018) Sex and gender differences in Alzheimer’s disease dementia. Psychiatric Times35, 14–17.
19.
ZenderR, OlshanskyE (2009) Women’s Mental Health: Depression and anxiety. Nurs Clin North Am44, 355–364.
20.
GeorgeEK, ReddyPH (2019) Can healthy diets, regular exercise, and better lifestyle delay the progression of dementia in elderly individuals?J Alzheimers Dis72(s1), S37–S58.
21.
WellerJ, BudsonA (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research7, 1161.
22.
BloomGS (2014) Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol71, 505.
23.
Colom-CadenaM, Spires-JonesT, ZetterbergH, BlennowK, CaggianoA, DeKoskyST, FillitH, HarrisonJE, SchneiderLS, ScheltensP, de HaanW, GrundmanM, van DyckCH, IzzoNJ, CatalanoSM (2020) The clinical promise of biomarkers of synapse damage or loss in alzheimer’s disease. Alzheimers Res Ther12, 21.
24.
ReddyPH, TripathiR, TroungQ, TirumalaK, ReddyTP, AnekondaV, ShirendebUP, CalkinsMJ, ReddyAP, MaoP, ManczakM (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta1822, 639–649.
LahiriDK, MaloneyB, ZawiaNH (2009) The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry14, 992–1003.
29.
MaloneyB, LahiriDK (2016) Epigenetics of dementia: Understanding the disease as a transformation rather than a state. Lancet Neurol15, 760–774.
30.
LahiriDK, MaloneyB (2010) The “LEARn” (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer’s disease, and proposes remedial steps. Exp Gerontol45, 291–296.
31.
ReddyPH, ManczakM, YinXL (2017) Mitochondria-division inhibitor 1 protects against amyloid-β induced mitochondrial fragmentation and synaptic damage in Alzheimer’s disease. J Alzheimers Dis58, 147–162.
32.
SheladiaS, ReddyPH (2021) Age-related chronic diseases and Alzheimer’s disease in Texas: A Hispanic focused study. J Alzheimers Dis Rep5, 121–133.
BossGR, SeegmillerJE (1981) Age-related physiological changes and their clinical significance. West J Med135, 434–440.
38.
PetersR (2006) Ageing and the brain. Postgrad Med J82, 84–88.
39.
JuanSM, AdlardPA (2019) Ageing and cognition. Subcell Biochem91, 107–122.
40.
Rebelo-MarquesA, De Sousa LagesA, AndradeR, RibeiroCF, Mota-PintoA, CarrilhoF, Espregueira-MendesJ (2018) Aging hallmarks: The benefits of physical exercise. Front Endocrinol9, 258.
41.
TranM, ReddyPH (2021) Defective autophagy and mitophagy in aging and Alzheimer’s disease. Front Neurosci14, 612757.
42.
López-OtínC, BlascoMA, PartridgeL, SerranoM, KroemerG (2013) The hallmarks of aging. Cell153, 1194–1217.
43.
MichelJ-P, SadanaR (2017) “Healthy aging” concepts and measures. J Am Med Dir Assoc18, 460–464.
44.
Fernández-BallesterosR, RobineJM, WalkerA, KalacheA (2013) Active aging: A global goal. Curr Gerontol Geriatr Res2013, 1–4.
45.
FuchsJ, Scheidt-NaveC, HinrichsT, MergenthalerA, SteinJ, Riedel-HellerS, GrillE (2013) Indicators for healthy ageing —a debate. Int J Environ Res Public Health10, 6630–6644.
46.
ReddyPH, BlackmonJ, Molinar-LopezV, AmentC, ManczakM, KandimallaR, YinX, PandeyA, KuruvaCS, WangR, FryD, OsbornC, StonumK, QuesadaK, GonzalesR, BolesA (2015) Garrison Institute on Aging: A new hope for elderly individuals and patients with Alzheimer’s disease. J Alzheimers Dis48, 547–555.
47.
BlackmonJ, BolesAN, ReddyPH (2015) Garrison Institute on Aging—Lubbock Retired and Senior Volunteer Program (RSVP) provides services to South Plains, Texas. Front Aging Neurosci7, 215.
48.
BolesAN, KhanH, LenzmeierTA, Molinar-LopezVA, AmentJC, TeBrinkKL, StonumK, GonzalesRM, ReddyPH (2016) Impact of exercise and education in adults of Lubbock, Texas: Implications for better lifestyle. Front Aging Neurosci8, 85.
49.
BolesA, KandimallaR, ReddyPH (2017) Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis1863, 1026–1036.
50.
ReddyPH, SwerdlowRH, CulbersonJ, KangD, MitchellTL, SmithQ, SunejaS, OryMG, KumarS, VijayanM, MorsyA, ArandiaG, LawrenceJJ, GeorgeE, OliverD, PradeepkiranJA, YinX, ReddyAP, ManczakM, CengizP, KaramyanVT, KandimallaR, KuruvaCS, WillmsJ, RamasubramanianB, SawantN, BuruguD, BolesAN, LopezV, CarrascoR, AguirreC, ThompsonS, BlackmonJ, AmentC, WangR, StephensER, HoangB, BassK, TrippierPC, HornbackC, KottapalliP, KottapalliKR; Center Biotechnology and Genetics Core Facility, OddoS (2019) Current status of healthy aging and dementia research: A symposium summary. J Alzheimers Dis72(s1), S11–S35.
51.
KhanH, RafiqA, ShabanehO, GittnerLAS, ReddyPH (2019) Current issues in chronic diseases: A focus on dementia and hypertension in rural West Texans. J Alzheimers Dis72(s1), S59–S69.
52.
KhanH, RafiqA, PalleK, FayselM, GabbidonK, ChowdhuryM, ReddyPH (2021) Sex differences in cardiovascular disease and cognitive dysfunction in rural west elderly Texans. J Alzheimers Dis Rep5, 213–226.
53.
KhanH, TiwariP, KaurA, SinghTG (2021) Sirtuin acetylation and deacetylation: A complex paradigm in neurodegenerative disease. Mol Neurobiol58, 3903–3917.
54.
KhanH, RasmussenD, GittnerL, RafiqA, BlakelyS, ShabanehO, ReddyPH (2020) Gender differences in prevalence of myocardial infarction in rural West Texans. J Public Health30, 385–397.
55.
JohnA, AliK, MarshH, ReddyPH (2021) Can healthy lifestyle reduce disease progression of Alzheimer’s during a global pandemic of covid-19?Ageing Res Rev70, 101406.
56.
KhanH, RasmussenD, GabbidonK, PalleK, RafiqA, FayselM, SinghS, ReddyPH (2021) Disparities in breast cancer survivors in rural West Texas. Cancer Control28, 107327482110421.
RolstadS, AdlerJ, RydénA (2011) Response burden and questionnaire length: Is shorter better? A review and meta-analysis. Value Health14, 1101–1108.
59.
MarcuB, BosnjakM, LindnerS, PilischenkoS, SchützA (2007) Compensating for low topic interest and long surveys: A field experiment on nonresponse in web surveys. Soc Sci Comput Rev25, 372–383.
60.
HerzogAR, BachmanJG (1981) Effects of questionnaire length on response quality. Public Opin Q45, 549–559.
61.
McFarlandSG (1981) Effects of question order on survey responses. Public Opin Q45, 208–215.
62.
LaffitteRG (1984) Effects of item order on achievement test scores and students’ perception of test difficulty. Teach Psychol11, 212–214.
63.
Hopman-RockM, van HirtumH, de VreedeP, FreibergerE (2019) Activities of daily living in older community-dwelling persons: A systematic review of psychometric properties of instruments. Aging Clin Exp Res31, 917–925.
64.
DeyoRA, CherkinDC, CiolMA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol45, 613–619.
65.
PalinkasLA, HorwitzSM, GreenCA, WisdomJP, DuanN, HoagwoodK (2015) Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Admin Policy Mental Health42, 533–544.
66.
ATLAS.ti Scientific Software Development GmbH. version 7.5.16 Version 9.5.16. Cologne, Germany 2019. [computer program].
67.
ThomsonR, BrinkworthGD, BuckleyJD, NoakesM, CliftonPM (2007) Good agreement between bioelectrical impedance and dual-energy X-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women. Clin Nutr26, 771–777.
68.
EckertS, GleichmannU, ZagorskiO, KlappA (1997) Validation of the OMRON R3 blood pressure self-measuring device through simultaneous comparative invasive measurements according to protocol 58130 of the German Institute for Validation. Blood Press Monit2, 189–192.
69.
Jilcott PittsSB, JahnsL, WuQ, MoranNE, BellRA, TruesdaleKP, LaskaMN (2018) A non-invasive assessment of skin carotenoid status through reflection spectroscopy is a feasible, reliable and potentially valid measure of fruit and vegetable consumption in a diverse community sample. Public Health Nutr21, 1664–1670.
70.
FreitasS, SimõesMR, AlvesL, VicenteM, SantanaI (2012) Montreal Cognitive Assessment (MoCA): Validation study for vascular dementia. J Int Neuropsychol Soc18, 1031–1040.
71.
McEvoyLK, BrewerJB (2010) Quantitative structural MRI for early detection of Alzheimer’s disease. Expert Rev Neurotherap10, 1675–1688.
72.
AdlardPA, TranBA, FinkelsteinDI, DesmondPM, JohnstonLA, BushAI, EganGF (2014) A review of β-amyloid neuroimaging in Alzheimer’s disease. Front Neurosci8, 327.
